Drug Trial Radar · NCT06469151
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jun 24, 2024
Primary completion
Oct 22, 2025
Study completion Oct 22, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants
Conditions
- Healthy Participants
Interventions
AZD5148Drug
Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus
PlaceboDrug
Participants will receive matching doses of placebo as an IM injection or IV bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs).Time frame: From Day -1 to Day 91
- Number of participants with serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From Screening (Day -28 to Day -1) to final Follow-up Visit (Day 361 ± 14)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama
Research Site
Glendale, California
Research Site
Baltimore, Maryland
Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.